Revelations from the 2010 Sinusoid Symposium
Nestled within every human liver lies a microscopic universe of intricate cellular networksâthe hepatic sinusoids. These tiny blood vessels, no wider than a few hair widths, serve as the liver's command center for detoxification, immunity, and metabolism.
In 2010, 205 scientists from 21 nations converged in Pasadena, California, for the 15th International Symposium on Cells of the Hepatic Sinusoid (ISCHS). Their mission? To decode how these cells drive diseases like cirrhosis, hepatitis, and liver cancer 1 2 .
This meeting marked a milestoneâthe inaugural conference of the International Society for Hepatic Sinusoidal Research (ISHSR)âand unveiled breakthroughs that reshape our fight against liver diseases 4 .
Act as a "living sieve" with pores (fenestrae) that filter toxins while allowing nutrient exchange.
Breakthrough: Lose filtering in fatty liver disease 5
The liver's immune sentinels, phagocytizing bacteria and dead cells.
Switch states in alcoholism 1
Natural killer (NK) cells that eliminate infected or cancerous hepatocytes.
Surveil for tumors/infections 5
Mice lacking cannabinoid receptor 2 (CB2) developed severe alcoholic liver injury. Activating CB2 switched KCs to anti-inflammatory states 1 .
Therapeutic Implication: CB2 agonists could treat alcoholic hepatitis.
Led by Ekihiro Seki (UC San Diego), this study asked: Which cells license alcohol to destroy the liver? 1
Mouse Group | Steatosis | Inflammation | Fibrosis | Conclusion |
---|---|---|---|---|
WT mice + WT bone marrow | Severe | Severe | Moderate | Full injury |
TLR4â/â + TLR4â/â bone marrow | None | None | None | Complete protection |
TLR4â/â + WT bone marrow | Moderate | Moderate | Mild | KCs drive 50% of injury |
WT mice + TLR4â/â bone marrow | Moderate | Moderate | Mild | HSCs drive 50% of injury |
Drugs must target multiple cell types to halt alcohol-induced damage.
Liver sinusoidal research relies on precision tools. Here are the 2010 symposium's stars:
Reagent | Function | Example Use |
---|---|---|
TLR4 antibodies | Block endotoxin signaling | Prevent alcohol-induced KC/HSC activation |
CB2 agonists | Activate anti-inflammatory pathways | Switch KCs from M1 to M2 states |
Hedgehog inhibitors | Block Shh/Ihh from injured hepatocytes | Reduce HSC activation in fatty liver |
FXR ligands (e.g., INT-747) | Activate bile acid receptors | Improve NASH/fibrosis in preclinical models |
GRP78-deficient mice | Model endoplasmic reticulum (ER) stress | Study ER stress in drug-induced injury |
The 15th ISCHS symposium wasn't just a meetingâit was a catalyst. By exposing how TLR4, hedgehog signals, and cannabinoid receptors orchestrate liver disease, researchers identified actionable drug targets.
Today, clinical trials are evaluating CB2 agonists for alcoholic hepatitis and FXR ligands for NASH 4 . As ISHSR president Hidekazu Tsukamoto noted, "The sinusoid is where liver diseases beginâand where they'll be conquered." With the 20th ISCHS slated for 2025, the hidden universe in our livers is finally yielding its secrets 6 .
For further reading, see the meeting report in Liver International (2011) 2 .